VDPHL is under clinical development by Veradermics and currently in Phase II for Androgenic Alopecia. According to GlobalData, Phase II drugs for Androgenic Alopecia does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the VDPHL LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
VDPHL overview
VDPHL is under development for the treatment of androgenetic alopecia (pattern hair loss). It is administered through oral route as a tablet.
Veradermics overview
Veradermics focuses on the development and advancement of first-in-class therapeutics to address patient needs in the field of dermatology. The company is headquartered in New Haven, Connecticut, the US.
For a complete picture of VDPHL’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
